Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 15, 2018
Pharmacy Choice - Pharmaceutical News - Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer - October 15, 2018

Pharmacy News Article

 11/20/17 - Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer

By a News Reporter-Staff News Editor at Cancer Vaccine Week Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax?, has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) allowing Batu to proceed with Phase 1 clinical trials. To the company's knowledge, this is the first polyvalent immunotherapy cleared by the FDA that targets the blood vessels that feed cancer. ValloVax was inspired by the original research of Dr. Valentin Ivanovich Govallo who observed tumor regression of advanced cancer patients subsequent to placental immunization. ValloVax is a defined, off the shelf, cellular therapy that specifically induces immune responses against the tumor vasculature (see also Batu Biologics).

"It has been my honor to lead the clinical development and manufacturing of the ValloVax vaccine, which is comprised of placental stem cell-like cells generated under Good Manufacturing Practices (GMP) at the University of Miami," said Dr. Amit Patel, Director of Biologic Innovation in the Department of Surgery at University of Miami and National Principal Investigator of the Batu clinical trial. "We believe that leveraging of the immune system to block angiogenesis, or new blood vessel growth, is a highly promising approach."

Batu Biologics has previously published in peer reviewed literature that ValloVax is effective in treating lung, colon, breast, brain and skin cancer in animal models.1,2 "It is our hope that ValloVax, our novel immune therapy, will treat cancer by training the immune system to kill tumor-associated blood vessels," said Dr. Alan Lewis, Chairman of Batu Biologics. "Blood vessel formation is associated with malignancy and metastatic activity in established tumors, and ValloVax may have clinical benefit in treating multiple cancers."

Lewis continued, "With the recent IND approval, our 25-year old president and CEO, Samuel Wagner, has become one of the youngest CEOs to ever lead a life science company through a successful IND filing with the FDA. I am very excited to guide the Company through the drug development process in the next steps for the company."

ValloVax is a polyvalent cancer vaccine that stimulates an immune response against the tumor-associated blood vessels, seeking to cut off the blood supply required for sustainable tumor growth. Mechanistic studies have indicated that ValloVax triggers both a cell-mediated and antibody-mediated response that is specific to cancer blood vessels and not healthy blood vessels.2 Batu Biologics has also previously published three case study reports of end stage cancer patients treated with ValloVax in an Investigator-initiated, compassionate use setting where safety and demonstration of cancer blood vessel specific immune response was observed.3 "Our team of collaborators and investors have worked tirelessly in bringing the first 'multivalent angiogenesis targeted cancer immunotherapy' to patients in the U.S.," said Wagner. "While current advances in immunotherapy have improved prognosis in specific types of cancers, at present only 20 percent of patients respond to conventional immunotherapy, such as checkpoint inhibitors. The fact that ValloVax possesses potent anticancer activity when used alone in mouse models, combined with the demonstrated synergy with checkpoint inhibitors2, means to us that ValloVax could be another potent weapon in our fight against cancer."

Keywords for this news article include: Biotechnology, Cancer, Oncology, Angiogenesis, Immunotherapy, Batu Biologics, Bioengineering, Drugs and Therapies, Genetic Engineering, Genetically-Engineered Proteins, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 16: Management of Alcohol Use Disorders
Last Chance
Oct 17: Telepharmacy- Remote Delivery of Pharmacy Services
Oct 18: Obesity Management: Overview of Pharmacotherapy
Oct 22: An Integrative Approach to Managing Arthritis
Oct 23: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement